secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verastem, Inc. (VSTM)
CIK:        0001526119
Form:       8-K
Filed at:   2025-12-19T23:59:59+00:00
Accession:  0001104659-25-123295
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verastem: new chairman, president of development appointed; COO departs; RAMP 301 enrollment complete
--------------------------------------------------------------------------------

- John Johnson appointed chairman of board; Michael Kauffman, MD, PhD, becomes president of development, leaving lead director role.
- Matthew Ros, COO, departs; receives nine-month base salary continuation and pro-rated bonus under separation agreement.
- RAMP 301 Phase 3 trial in recurrent LGSOC completed additional enrollment of 29 patients; topline data expected mid-2027.
- Commercial launch of AVMAPKI FAKZYNJA CO-PACK progressing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1526119/000110465925123295/0001104659-25-123295-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1526119/000110465925123295/tm2533463d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-123295

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer